RESUMO
Canrenon, an active metabolite of spironolactone, and the combination of Canrenon with hydrochlorothiazide (HCT) were examined on patients with essential hypertension, cardial oedemas and oedemas of different origin, and than compared to a product available on the market. A correlation of the clinical effect (e.g. systolic blood pressure) with the morning steady state-data (blood values of Canrenon and HCT) has been achieved. The new preparations showed a good resorption in the gastro-intestinal tract. For an equivalent clinical effect, less Canrenon substance has been needed. A therapeutically satisfactory result has been reached with the administered dosage of both Canrenon and the comparison group. In the combination the higher dosage level should be chosen.